Results 221 to 230 of about 4,368 (233)
Some of the next articles are maybe not open access.

The role of the GH receptor polymorphisms as a prognostic factor of vertebral fractures in acromegalic patients resistant to first-generation SSAs and treated with Pegvisomant or Pasireotide Lar

Endocrine Abstracts, 2023
F. Costanza   +11 more
semanticscholar   +1 more source

Second line treatment of acromegaly: Pasireotide or Pegvisomant?

Best practice & research. Clinical endocrinology & metabolism, 2022
S. Chiloiro   +5 more
semanticscholar   +1 more source

Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess.

Best practice & research. Clinical endocrinology & metabolism
James MacFarlane, Márta Korbonits
semanticscholar   +1 more source

Efficacy, safety and metabolic impact of long-term pegvisomant therapy in acromegaly: results from a 10-year single center experience

Endocrine Abstracts, 2022
R. Pirchio   +5 more
semanticscholar   +1 more source

Pegvisomant in the treatment of acromegaly

Pharmateca
Rebrova E.V. Rebrova   +1 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy